Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
SARS-CoV-2COVID-19Post-Acute COVID-19 Syndrome
Interventions
BIOLOGICAL

Pfizer-BioNTech COVID-19 mRNA vaccine

Pfizer-BioNTech COVID-19 Vaccine, is FDA licensed or authorized under Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY